NUC-7738 is under clinical development by NuCana and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs for Lymphoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NUC-7738’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NUC-7738 overview
NUC-7738 is under development for the treatment of solid tumors including metastatic cutaneous melanoma, metastatic lung adenocarcinoma, metastatic clival chordoma, B-cell non-Hodgkin lymphomas (NHL), Hodgkin's lymphoma, T-cell lymphomas, lymphoma and kidney cancer. It is administered through intravenous route as an infusion. The drug candidate is a ProTide transformation of 3’-deoxyadenosine (3’-dA) phosphoramidate, an adenosine derivative which is isolated from Cordyceps sinensis. It acts by targeting adenosine monophosphate activated protein kinase (AMPK) and is being developed based on ProTide technology.
NuCana overview
NuCana is a clinical-stage biopharmaceutical company that develops novel and transformational medicines for the treatment of cancer. The company pipeline products include NUC-3373 targets advanced colorectal cancer; NUC-7738 for advanced solid tumors; acelarin (NUC-1031); and NuTide 121 treats metastatic biliary tract cancer, gemcitabine for biliary tract cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, bladder and breast cancers. NuCana develops products based on the ProTide technology platform, which focuses on developing new-generation, anti-cancer agents. The company operates in the UK and the US. NuCana is headquartered in Edinburgh, Scotland, the UK.
For a complete picture of NUC-7738’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
